Oaktree Acquisition Corp. III Life Sciences (OACC) Liabilities and Shareholders Equity (2024 - 2026)

Oaktree Acquisition Corp. III Life Sciences has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $204.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 3.85% year-over-year to $204.8 million; the trailing twelve-month figure through Mar 2026 stood at $808.4 million (changed N/A YoY), and the FY2025 full-year result was $203.1 million, up 4.03% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $204.8 million, up from $203.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $204.8 million in Q1 2026, with the low at $195.3 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $200.1 million across 3 years, with a median of $200.2 million in 2025.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity gained 4.03% — and 2026, when it climbed 3.85%.
• Oaktree Acquisition Corp. III Life Sciences' Liabilities and Shareholders Equity stood at $195.3 million in 2024, then climbed by 4.03% to $203.1 million in 2025, then advanced by 0.85% to $204.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $204.8 million (Q1 2026), $203.1 million (Q4 2025), and $201.2 million (Q3 2025), per Business Quant data.